Outcome of Chemotherapeutic Regimens Cisplatin and 5-Fluorouracil vs Weekly 5-Fluorouracil in Advanced Gastric Cancer

ABSTRACT

Introduction: Gastric cancer is the second leading cause ofcancer death worldwide, with a 5-year survival rate of lessthan 20%. About 25% of patients with gastric cancer presentwith disseminated disease and more than half of those withapparently localized disease recur within 5 years. Study aimedto evaluate the response rate, median PFS, overall survivaland toxicity to 3 Weekly Cisplatin/5-Fluorouracil Vs Weekly5-Fluorouracil in patients with advanced gastric cancer.Material and Methods: Patients were recruited forchemotherapy with Cisplatin 75mg/mg2 in divided dosesand 5-Fluorouracil 750mg/m2 for 3 days in every 21 daysfor 6 cycles in one arm and 20 patients for treatment withWeekly 5- Fluorouracil 500mg for 16 weeks. Within twomonths of completion of chemotherapy, CT abdomen wasdone to compare with the baseline CT abdomen to assess theresponse rate using RESIST criteria Version V1.1. Also theimprovement in ECOG PS was ascertained as an endpoint.Results: In the Cisplatin /5FU arm had an overall response rateof 20%, median PFS of 6 months,45% had a partial response(PR), 10% had stable disease (SD) 25% had progression(PD), 20% achieved CR and more of haematological andnon-hematological toxicity. In the 5FU arm, 35% had stabledisease (SD),40% had progression (PD) 5% achieved CR andless of haematological and non-hematological toxicity.Conclusion: In advanced gastric cancer, Cisplatin /5FU hadmore response rate, more median PFS and more toxicity.Weekly 5FU is better tolerable regimen with